Test Price
800 AED✅ Home Collection Available
Cytochrome P450 2C19 Genotyping (CYP2C19) Clopidogrel Resistance (*2,*3,*4,*10) in UAE | 800 AED | DHA-Licensed & Approved
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing at our UAE facility.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across Dubai, Abu Dhabi, Sharjah.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed genetic counselors.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This pharmacogenetic test identifies inherited variants in the CYP2C19 gene—specifically loss-of-function alleles *2, *3, *4, and *10—that predict poor metabolism of the antiplatelet drug clopidogrel, enabling personalized anti-thrombotic therapy. Preferred by Gynecologists managing post-menopausal cardiovascular risk, Anti-Aging Specialists optimizing longevity therapies, and Family Medicine Physicians ensuring safe chronic pharmacotherapy.
| Feature | Our Test (UAE Golden Standard) | Standard Genotyping |
|---|---|---|
| Precision | Sanger Sequencing (Gold Standard), 100% allele coverage for *2, *3, *4, *10 | PCR-RFLP or targeted arrays, may miss rare variants |
| Turnaround | 7 Working Days (Expedited Available) | 10–14 Days |
| Clinical Reporting | DHA-compliant, actionable phenotype: Extensive, Intermediate, Poor Metabolisers | Basic genotype only |
Physician Insight & Safety Protocols
“CYP2C19 genotyping is a powerful tool to guide clopidogrel therapy, but it must always be interpreted within the full clinical context including bleeding risk, comorbidities, and concomitant medications. Never discontinue antiplatelet therapy without consulting your cardiologist or prescribing physician. Our laboratory ensures results are delivered with actionable phenotype classifications and DHA-compliant reporting.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠ Medication Safety Advisory
Do not stop prescribed clopidogrel or any antiplatelet medication without explicit guidance from your doctor. Abrupt discontinuation may lead to stent thrombosis, myocardial infarction, or other life-threatening cardiovascular events. This test is intended solely to inform therapeutic adjustments under direct medical supervision.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients with active bleeding, known hypersensitivity to anticoagulants, or recent major surgery within 30 days are not suitable for home sample collection without prior stabilization.
- Exclusion: Pregnant or breastfeeding women require specific DHA-approved consent forms.
- Red Flag: If you experience sudden chest pain, shortness of breath, or uncontrolled bleeding after the test, call 998 immediately.
Patient FAQ & Clinical Guidance
1. What does the CYP2C19 genotype mean for my clopidogrel therapy?
CYP2C19 genotyping identifies whether you are a normal, intermediate, or poor metaboliser of clopidogrel, directly impacting the drug’s effectiveness in preventing heart attacks and strokes. Poor metabolisers may have up to a 3-fold higher risk of stent thrombosis and require alternative antiplatelet strategies such as prasugrel or ticagrelor, always under specialist guidance.
2. Is a doctor’s prescription required for this test in the UAE?
Yes, a valid DHA-registered doctor’s prescription is mandatory for CYP2C19 genotyping to ensure clinical appropriateness, in compliance with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields and Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
3. How is the sample collected and what are the turnaround times?
A peripheral blood sample is collected via VIP Mobile Phlebotomy at your home or office (available daily 8 AM–11 PM) or at our partner clinics. Results are reported within 7 working days with expedited options available. The sample is processed under ISO 9001:2015 accredited protocols.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to the UAE’s comprehensive legal framework for health data and genetic privacy. All test results are encrypted and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic data is never shared without explicit written consent.
Clinical & Logistical Metadata
| Test Name | Cytochrome P450 2C19 Genotyping (CYP2C19) Clopidogrel Resistance (*2,*3,*4,*10) |
| Price (AED) | 800 |
| Turnaround Time | 7 Working Days (Expedited Available) |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Sanger Sequencing (Gold Standard) |
| ICD-10-CM Code | Z13.81 (Encounter for genetic screening) |
| LOINC Code | 65737-8 (CYP2C19 gene mutations detected in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians